A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.

ABSTRACT: A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore, EGFR amplification were observed in 2/4 (50%) responders with average copy number 5.8 and >15 respectively. Our data suggest that a GC subtype with EGFR amplification and overexpression benefit from cetuximab treatment.

SUBMITTER: Zhang L 

PROVIDER: S-EPMC3801116 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature